EX-23.1 5 slrx12312019eyconsent1.htm EX-23.1 Document

Exhibit 23.1


Consent of Independent Registered Public Accounting Firm


We consent to the incorporation by reference in the following Registration Statements:

a.Registration Statement (Form S-8 No. 333-201816) pertaining to the 2014 Equity Incentive Plan, 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of Salarius Pharmaceuticals, Inc. (formerly known as Flex Pharma, Inc.);
b.Registration Statement (Form S-8 Nos. 333-210283, 333-216534, 333-223499 and 333-230104) pertaining to the 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of Salarius Pharmaceuticals, Inc. (formerly known as Flex Pharma, Inc.);
c.Registration Statement (Form S-3 No. 333-210289 and 333-231010) of Salarius Pharmaceuticals, Inc. (formerly known as Flex Pharma, Inc.);
d.Registration Statement (Form S-1 No. 333-235879) of Salarius Pharmaceuticals, Inc.

of our report dated March 23, 2020, with respect to the consolidated financial statements of Salarius Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Salarius Pharmaceuticals, Inc. for the year ended December 31, 2019.

/s/ Ernst & Young LLP


Houston, Texas
March 23, 2020